secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2026-07-10T21:13:07+00:00
Accession:  0001104659-26-082719
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar shareholders approve warrant exercise for up to 39.6M shares, increase share reserve by 2M
--------------------------------------------------------------------------------

- Class III directors Andrew Gu and Douglas J. Swirsky elected to three-year terms.
- Shareholders approved 2,000,000 share increase under 2021 Stock Incentive Plan.
- Shareholders approved exercise of warrants for up to 39,618,078 shares of common stock.
- Deloitte & Touche ratified as independent auditor for fiscal year 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/0001104659-26-082719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/tm2620219d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer